Journal Watch · Frontiers in Immunology · 2026
Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression.
Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.<h4>Conclusion</h4>Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.
TL;DR
Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.<h4>Conclusion</h4>Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.
Key findings
- To understand the impact of BETd on TME populations, we performed single-cell RNA sequencing, which identified myeloid cells as the predominant population.
- BETd reduced MRC1⁺immunoregulatory tumor-associated macrophages and enriched CD74+ antigen-presenting macrophages, with upregulated phagosome pathways and enhanced Stat1 activation. <i>In vitro</i>, BETd downregulated M2-associated markers, promoted macrophage phagocytosis, induced tumor cell apoptosis, and inhibited macrophage-driven CSC formation.
- Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.<h4>Conclusion</h4>Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.
What they did
NK cells or macrophages were depleted to determine their contribution to BETd response. <i>In vitro</i>, primary murine NK cells, bone marrow-derived macrophages, and THP-1, NK-92 MI, SUM-149, and D2A1 cells were used for co-culture, transwell migration, phagocytosis, qPCR, ELISA, and flow cytometry assays. Single-cell RNA sequencing (scRNA-seq) was performed using 10x Genomics 3' sequencing and analyzed with Seurat.<h4>Results and discussion</h4>ZBC260 inhibited tumor growth in SCID mice but not in NOD-SCID mice, with impaired macrophages and partially compromised NK cells, implicating the innate immune system. To assess the contribution of innate immune cells to BETd efficacy, we depleted NK cells or macrophages in immunocompetent BALB/c mice with D2A1 tumors and treated with ZBC260 or vehicle. Immune depletion studies revealed macrophage loss partially attenuated anti-tumor and anti-CSC effects, highlighting their critical role.
Full abstract (original)
Background: <h4>Introduction</h4>Breast cancer (BC) remains a leading cause of cancer-related deaths, with resistance to therapy driving tumor progression. While immune checkpoint inhibitor (ICI) therapy is effective in some breast cancers, the heterogeneity of treatment responses is partly driven by cancer stem cells (CSCs) and an immunosuppressive tumor microenvironment (TME). Bromodomain and extra-terminal (BET) proteins regulate tumor and immune biology, but their role in innate anti-tumor immunity remains poorly understood. We investigated the role of BET proteins in modulating innate immunity using the potent BET degrader (BETd) ZBC260.<h4>Methods</h4>ZBC260 efficacy was evaluated in immunocompetent BALB/c mice bearing D2A1 tumors.
What they did: NK cells or macrophages were depleted to determine their contribution to BETd response. <i>In vitro</i>, primary murine NK cells, bone marrow-derived macrophages, and THP-1, NK-92 MI, SUM-149, and D2A1 cells were used for co-culture, transwell migration, phagocytosis, qPCR, ELISA, and flow cytometry assays. Single-cell RNA sequencing (scRNA-seq) was performed using 10x Genomics 3' sequencing and analyzed with Seurat.<h4>Results and discussion</h4>ZBC260 inhibited tumor growth in SCID mice but not in NOD-SCID mice, with impaired macrophages and partially compromised NK cells, implicating the innate immune system. To assess the contribution of innate immune cells to BETd efficacy, we depleted NK cells or macrophages in immunocompetent BALB/c mice with D2A1 tumors and treated with ZBC260 or vehicle. Immune depletion studies revealed macrophage loss partially attenuated anti-tumor and anti-CSC effects, highlighting their critical role.
Results & conclusions: To understand the impact of BETd on TME populations, we performed single-cell RNA sequencing, which identified myeloid cells as the predominant population. BETd reduced MRC1⁺immunoregulatory tumor-associated macrophages and enriched CD74+ antigen-presenting macrophages, with upregulated phagosome pathways and enhanced Stat1 activation. <i>In vitro</i>, BETd downregulated M2-associated markers, promoted macrophage phagocytosis, induced tumor cell apoptosis, and inhibited macrophage-driven CSC formation. Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.<h4>Conclusion</h4>Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1738705 · PubMed 42756154.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.<h4>Conclusion</h4>Collectively, these findings demonstrate that BETd ZBC260 reshapes the TME and reprograms macrophages toward an anti-tumor phenotype, highlighting its translational potential for breast cancer therapy.
What type of study is this?
It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. NK cells or macrophages were depleted to determine their contribution to BETd response.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1738705. PubMed ID: 42756154. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-bromodomain-and-extra-terminal-proteins-reprograms-macrophages-738705/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides